Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04409080
Recruitment Status : Not yet recruiting
First Posted : June 1, 2020
Last Update Posted : September 29, 2020
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The primary objective of this study is to assess the safety and tolerability of REGN7257 in patients with severe aplastic anemia (SAA) that is refractory to or has relapsed while on standard of care immunosuppressive therapy (IST). An additional primary objective (for Part B only) is to evaluate the clinical efficacy of REGN7257 in IST-refractory/relapsed patients.

The secondary objectives of this study are to assess the following for REGN7257:

  • Clinical response over time
  • Maintenance of response
  • Impact on transfusion requirements
  • Effect on blood counts and cell populations
  • Pharmacokinetics (PK)
  • Immunogenicity

Condition or disease Intervention/treatment Phase
Severe Aplastic Anemia (SAA) Drug: REGN7257 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : August 23, 2023
Estimated Study Completion Date : August 23, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A and Part B
Part A: Single ascending dose Part B: Preferred dose
Drug: REGN7257
Single dose will be administered by intravenous IV infusion




Primary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: 12 months post-treatment, approximately 52 weeks ]
    Part A

  2. Incidence of serious adverse events (SAEs) [ Time Frame: 12 months post-treatment, approximately 52 weeks ]
    Parts A and B

  3. Incidence and severity of treatment-emergent adverse events (TEAEs) up [ Time Frame: 12 months post-treatment, approximately 52 weeks ]
    Parts A and B

  4. Overall response rate (ORR) [ Time Frame: 6 months post-treatment, approximately 26 weeks ]
    Part B


Secondary Outcome Measures :
  1. ORR [ Time Frame: 3 months post-treatment, approximately 12 weeks ]
    Parts A and B

  2. Complete response (CR) [ Time Frame: 3 months post-treatment, approximately 12 weeks ]
    Parts A and B

  3. Partial response (PR) [ Time Frame: 3 months post-treatment, approximately 12 weeks ]
    Parts A and B

  4. Time to best response [ Time Frame: Up to 12 months ]
    Parts A and B

  5. Time to first response [ Time Frame: Up to 12 months ]
    Parts A and B

  6. Proportion of patients who maintain any clinical response [ Time Frame: Up to 12 months ]
    Parts A and B

  7. Platelet transfusions per month over time [ Time Frame: Up to 12 months ]
    Parts A and B

  8. Red blood cell transfusions per month over time [ Time Frame: Up to 12 months ]
    Parts A and B

  9. Changes in lymphocyte cell counts [ Time Frame: Up to 12 months ]
    Parts A and B

  10. Changes in neutrophil cell counts [ Time Frame: Up to 12 months ]
    Parts A and B

  11. Changes in hemoglobin cell counts [ Time Frame: Up to 12 months ]
    Parts A and B

  12. Changes in reticulocyte cell counts [ Time Frame: Up to 12 months ]
    Parts A and B

  13. Changes in platelet cell counts [ Time Frame: Up to 12 months ]
    Parts A and B

  14. Changes in the whole blood immune cell subsets (T cells) [ Time Frame: Up to 12 months ]
    Parts A and B

  15. Changes in the whole blood immune cell subsets (B cells) [ Time Frame: Up to 12 months ]
    Parts A and B

  16. Changes in the whole blood immune cell subsets (NK cells) [ Time Frame: Up to 12 months ]
    Parts A and B

  17. Drug concentrations in serum over time [ Time Frame: Up to 12 months ]
    Parts A and B

  18. Incidence of treatment-emergent anti-drug antibody (ADA) over time [ Time Frame: Up to 12 months ]
    Parts A and B



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • SAA that is refractory to or has relapsed while on standard of care IST, as defined in the protocol
  • Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a treatment option or has been refused by the patient
  • Adequate hepatic and renal function as defined in the protocol

Key Exclusion Criteria:

  • Diagnosis of Fanconi anemia as defined in the protocol
  • Evidence of myelodysplastic syndrome as defined in the protocol
  • Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of significant hemolysis or history of PNH-associated thrombosis
  • Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior to dosing
  • Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing
  • Treatment with eltrombopag or investigational thrombopoietin receptor agonist, Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2 weeks prior to dosing
  • HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit
  • Active tuberculosis, latent tuberculosis infection (LTBI) or history incompletely-treated tuberculosis or LTBI

Note: Other protocol-defined inclusion/ exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04409080


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04409080    
Other Study ID Numbers: R7257-RAA-1947
2020-002031-29 ( EudraCT Number )
First Posted: June 1, 2020    Key Record Dates
Last Update Posted: September 29, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access Criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Immunosuppressive therapy (IST)
Refractory
Relapsed
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Anemia, Aplastic
Hematologic Diseases
Bone Marrow Diseases